Hepatology
Experts in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials
The voice of MASH investigators
Global survey provides insights for trial operations
Metabolic dysfunction-associated steatohepatitis (MASH), a component of metabolic syndrome, is an area of very active clinical development. To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of MASH clinical trial sites across 37 different countries.
Digital solutions to alleviate MASH clinical trial challenges
The performance of MASH clinical trials presents many challenges unique to the field. Watch the on-demand webinar to learn about:
- The ability for digital technologies MRI, MRE and whole slide imaging to address MASH clinical trial challenges
- The ability of MRI and MRE to provide timely, high quality non-invasive solutions to enrolment
- The ability of whole slide imaging to facilitate rapid complex workflows that assure consistent high quality assessments of primary efficacy endpoints by enabling expert histopathologists to interact remotely and in real time.
Helping MASH study sites to succeed
Get insights and feedback from our extensive MASH study experience, and the findings from ICON’s survey of more than 2,000 sites across 30 countries including:
- How to best support global MASH sites to succeed in a competitive environment
- Optimising the operational strength of study sites to collectively support the MASH pipeline
- How understanding global and regional nuances can enhance MASH site patient recruitment and operational strategy
Metabolic dysfunction-associated steatohepatitis (MASH) clinical trials
Join Andrew Roche, PhD, a senior member of ICON's MASH team, as he speaks about overcoming the challenges and considerations associated with MASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
Blogs and media contributions
-
.jpeg?crop=yes&w=545&h=286&itok=tXlgRb-d "obesity_scan_icons")
Media article: Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
Media article: ICON launches multi-indication trial design service for obesity drugs
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO ICON.
-
.jpeg?crop=yes&w=545&h=286&itok=rCH0CGZP "obesity scan person")
Media article: More efficient next-gen obesity clinical trials needed, says survey
In this DDW article, discover key findings of an ICON survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
.jpeg?crop=yes&w=545&h=286&itok=EojYWs74 "obesity scan person")
Press release: Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: Expanding diagnostic and biomarker options to improve MASH clinical trials
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
.jpeg?crop=yes&w=1665&h=876&a=0,71&itok=-R3klXmC "obesity_scan_icons"){kind=icon}
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=QikrQ6DU "obesity scan person"){kind=icon}
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=4uJjfwGx "obesity scan person"){kind=icon}
Hepatology solutions
Discover more about ICON's solutions in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials clinical trials experts.